McAdam LLC’s Celldex Therapeutics CLDX Stock Holding History

McAdam LLC’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-3	Closed	–	–	146
2018 Q3	$0	Hold	3	–	–	﹤0.01%	668
2018 Q2	$0	Buy	+3	New	+$40	﹤0.01%	662

Other funds holding CLDX

CAM

Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return

KLP Enterprises Branford, Connecticut $1.97M AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCMG

TSP Capital Management Group Summit, New Jersey $410M AUM 71.81% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

McAdam LLC's CLDX Position: Q4 2018 in Review

McAdam LLC sold out of Celldex Therapeutics (CLDX) in Q4 2018, closing a stake of 3 shares.

McAdam LLC first reported a position in CLDX in Q2 2018 and held it in 2 quarters. The position peaked at $0 in Q3 2018. 85 funds tracked by Wall St. Rank hold CLDX as of Q4 2018.

McAdam LLC reported no remaining Celldex Therapeutics position as of Q4 2018 after selling out during the quarter.
McAdam LLC sold 3 Celldex Therapeutics shares in Q4 2018.
McAdam LLC first reported a position in Celldex Therapeutics in Q2 2018 and held it in 2 quarters.
McAdam LLC's Celldex Therapeutics position peaked at $0 in Q3 2018.
85 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2018.

Based on McAdam LLC's 13F filing for Q4 2018, filed 30 Jan 2019.